Infigratinib Gets FDA Priority Review for Achondroplasia
FDA accepts the oral infigratinib NDA for achondroplasia with Priority Review and a 4 February 2027 goal date. See the PROPEL 3 data and what happens next.
CSL Alentis Partnership: $1.6B Lixudebart Deal Explained
CSL pays $355M upfront in a partnership with Alentis to co-develop lixudebart for rare kidney and liver diseases, worth up to about $1.6B.